PMS2: a potential prognostic protein marker in oral squamous cell carcinoma.
| Autor: | Decker JM; Department of Dentistry, Unichristus Rua João Adolfo Gurgel 133 60192-345, Fortaleza, Ceará, Brazil paulo_goberlanio@yahoo.com.br., Filho OV, Freitas MO, Silva-Fernandes IJ, Dantas TS, Campêlo CS, Cunha MD, Silva PG, Sousa FB |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Medicina oral, patologia oral y cirugia bucal [Med Oral Patol Oral Cir Bucal] 2021 Jul 01; Vol. 26 (4), pp. e451-e458. Date of Electronic Publication: 2021 Jul 01. |
| DOI: | 10.4317/medoral.24303 |
| Abstrakt: | Background: An increase in oral squamous cell carcinoma (OSCC) cases was observed despite the reduction in exposure to classic risk factors. Although the exact cause of this trend remains unknown, epigenetic factors could be contributing to an increased occurrence of these tumors. This study aims to assess the influence of PMS2 protein immunoexpression on the prognosis of patients with OSCC. Material and Methods: This study comprised 76 cases of OSCC treated between 2011 and 2016. Immunohistochemical staining for PMS2 was performed. For evaluation, 10 fields per histological section were photographed at a 400x magnification and positively-stained cells were counted with Image J. Mann-Whitney and Kruskal-Wallis tests were used to compare the immunolabeling pattern with the clinical-pathological and prognostic characteristics. Survival analysis was performed with Chi-square, Long-Rank Mantel-Cox and Cox regression tests (p<0.05). Results: An overexpression of PMS2 was observed in N0/1 tumors and in oral cancers found in unusual locations. In patients ≤60 years of age, high levels of PMS2 (>60%; p=0.041) were associated with low survival (p=0.029). In multivariate analysis, surgery combined with chemotherapy (p=0.030) and high PMS2 immunoexpression (p=0.042) significantly increased the risk of death for ≤60 years old patients. Conclusions: The findings of this study indicate that PMS2 can be a potential prognostic protein marker in OSCC patients 60 years of age and younger. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|